You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

PATADAY TWICE DAILY RELIEF Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Pataday Twice Daily Relief patents expire, and what generic alternatives are available?

Pataday Twice Daily Relief is a drug marketed by Alcon Labs Inc and is included in one NDA.

The generic ingredient in PATADAY TWICE DAILY RELIEF is olopatadine hydrochloride. There are seventeen drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the olopatadine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Pataday Twice Daily Relief

A generic version of PATADAY TWICE DAILY RELIEF was approved as olopatadine hydrochloride by APOTEX INC on October 8th, 2014.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for PATADAY TWICE DAILY RELIEF?
  • What are the global sales for PATADAY TWICE DAILY RELIEF?
  • What is Average Wholesale Price for PATADAY TWICE DAILY RELIEF?
Drug patent expirations by year for PATADAY TWICE DAILY RELIEF
Recent Clinical Trials for PATADAY TWICE DAILY RELIEF

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Andover Research Eye InstitutePhase 4
AllerganPhase 4
McCabe Vision CenterN/A

See all PATADAY TWICE DAILY RELIEF clinical trials

Pharmacology for PATADAY TWICE DAILY RELIEF
Paragraph IV (Patent) Challenges for PATADAY TWICE DAILY RELIEF
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
PATADAY TWICE DAILY RELIEF Ophthalmic Solution olopatadine hydrochloride 0.1% 020688 1 2006-07-17

US Patents and Regulatory Information for PATADAY TWICE DAILY RELIEF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alcon Labs Inc PATADAY TWICE DAILY RELIEF olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020688-001 Dec 18, 1996 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PATADAY TWICE DAILY RELIEF

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alcon Labs Inc PATADAY TWICE DAILY RELIEF olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020688-001 Dec 18, 1996 ⤷  Sign Up ⤷  Sign Up
Alcon Labs Inc PATADAY TWICE DAILY RELIEF olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020688-001 Dec 18, 1996 ⤷  Sign Up ⤷  Sign Up
Alcon Labs Inc PATADAY TWICE DAILY RELIEF olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020688-001 Dec 18, 1996 ⤷  Sign Up ⤷  Sign Up
Alcon Labs Inc PATADAY TWICE DAILY RELIEF olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020688-001 Dec 18, 1996 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for PATADAY TWICE DAILY RELIEF

See the table below for patents covering PATADAY TWICE DAILY RELIEF around the world.

Country Patent Number Title Estimated Expiration
Australia 5726196 ⤷  Sign Up
European Patent Office 0351887 Composés tricycliques aromatiques. (Tricyclic aromatic compounds.) ⤷  Sign Up
Spain 2001519 PROCEDIMIENTO PARA PREPARAR COMPUESTOS AROMATICOS TRICICLICOS Y SU EMPLEO EN COMPOSICIONES FARMACEUTICAS. (Tricyclic compounds.) ⤷  Sign Up
World Intellectual Property Organization (WIPO) 9639147 ⤷  Sign Up
European Patent Office 0214779 TRICYCLIC COMPOUNDS ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for PATADAY TWICE DAILY RELIEF

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3043773 2190041-0 Sweden ⤷  Sign Up PRODUCT NAME: MOMETASONE OR A SALT THEREOF AND OLOPATADINE OR A SALT THEREOF; NAT. REG. NO/DATE: MT NR 60226 20210519; FIRST REG.: AT APPROVAL NR 140638 20210426
0799044 SPC029/2002 Ireland ⤷  Sign Up SPC029/2002: 20040930, EXPIRES: 20170516
3043773 2022C/520 Belgium ⤷  Sign Up PRODUCT NAME: MOMETASONE OF EEN ZOUT HIERVAN EN OLOPATADINE OF EEN ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: BE595626 20220203
3043773 21C1057 France ⤷  Sign Up PRODUCT NAME: MOMETASONE OU L'UN DE SES SELS AVEC OLOPATADINE OU L'UN DE SES SELS; NAT. REGISTRATION NO/DATE: NL52121 20211026; FIRST REGISTRATION: AT - 140638 20210426
0799044 CA 2002 00029 Denmark ⤷  Sign Up
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.